2nd Quarter Report

Second Quarter 2020 Report

July 16, 2020

Half-Year Revenues Increase 10-fold over Same Period in 2019

For the first 6 months of this year we generated over $1.5 million in revenue of which about $1.3 million was derived from sales of about 90,000 COVID-19 antibody tests. This compares to revenues of $149,000 during the same period in 2019.

Word writing text Live Webcast. Business concept for the process of video broadcasting live over the internet.

Financing Round Underway

Last week our equity crowdfunding campaign moved back to SeedInvest where we raised over $5 million in 2018. So far this year over $1.4 million has been raised.

20/20's campaign page may be accessed here . Please consider an investment and share with your network today.

Join our SeedInvest hosted investor webinar next Tuesday July 21 at 4:00 p.m. ET. CEO Jonathan Cohen will be discussing the new investment opportunity and answering questions live. Register for the webinar in advance with this link .

Ping An Medical to Commence Pilot w/ 20/20

20/20 entered a Memorandum of Understanding (MOU), effective June 5, with the Ping An Medical Group which includes Health Check-up Centers and diagnostic testing laboratories. The MOU, which may be viewed here, provides that 20/20's algorithms would be utilized on a trial basis in one or more of Ping An's Health Check Centers. If the pilot is successful the parties will move to a commercial arrangement.

Ping An is a digital healthcare powerhouse, ranked #29 on the Fortune 500 Global list, with over 300 million customers in China. A feature story discussing Ping An's leadership in big data and AI appeared last July in Fortune magazine and may be accessed here.

In 2016, Ping An invested $2 million in 20/20. They have a seat on our Board of Directors.

OneTest Algorithm Published in Respected Peer-Reviewed Oncology Journal

On June 1, a manuscript co-authored by scientists from 20/20 and the Chang Gung Memorial Hospital of Taiwan was published in the respected European oncology journal Cancers. A copy of this publication may be viewed here. Titled "Imp roving Multi-Tumor Biomarker Health Check-Up Tests with Machine Learning Algorithms" the paper concludes " ML-derived algorithms, trained and validated by using [real-world data] can significantly improve tumor marker-based screening for multiple types of early stage cancers, suggest the tissue of origin, and provide guidance for patient follow-up."

New Features Added to OneTest

Throughout the first half of 2020, our R&D team has been hard at work adding several new features to our multi-cancer early detection blood test including

A "universal algorithm" that permits various combinations biomarkers to be entered and analyzed. This feature, built with data from about 160,000 tested individuals from China and Taiwan, will be particularly useful in East Asia where there is great diversity in the biomarkers selected to be tested.
A "Time to Retest" feature that calculates the optimal time for a follow-up blood test.
A biomarker trends analysis tool that determines whether a change in biomarker levels over time is statistically significant.

Recruit Your Healthcare Provider & Get Free Yearly Cancer Screening for Life

Because of our success last year with equity crowdfunding under the new Regulation A+, 20/20 is fortunate to have over 4,000 shareholders throughout the U.S. and around the world. We are now seeking to leverage this substantial shareholder base to help grow test adoption worldwide.

We invite all shareholders to introduce OneTest to their doctor or medical screening provider. (We will provide you with a short hand-out to present to your doctor that summarizes the test's clinical performance and value.) If your introduction results in the healthcare provider routinely offering this test to patients, you will be entitled to a yearly OneTest™ for the rest of your life at no cost. (Available to US shareholders only)

For details, please contact Careen at ccarlton@2020gene.com or call 240-453-6339 x 108

Our previous Quarterly Reports and Press Releases may be downloaded here:

Financial Reports

In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those interested in obtaining copies of recently SEC filed Financial Statements, as well as unaudited interim statements, should contact RBrand@2020gene.com

Regulation A Offering and Forward Looking Statements

20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: https://www.seedinvest.com/2020.genesystems

A QUALIFIED OFFERING ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.